To evaluate how neurologists make decisions regarding chronic inflammatory demyelinating polyneuropathy (CIDP), we conducted a cross-sectional quantitative survey of 100 community neurologists in the United States. Only 13% cited using the European Federation of Neurological Societies/Peripheral Nerve Society guideline. In addition, variability in treatment approaches existed regarding the dose of IVIg used, the length of IVIg therapy before determining response, the outcome measures used to determine IVIg response, and the protocol for weaning off therapy. Forty-three percent reported giving doses that were lower than the recommended IVIg loading dose for CIDP. 
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overuse and/or misuse of long-term therapy for CIDP. [3] As IVIg is an effective yet expensive treatment, it is imperative that patients are neither denied treatment nor maintained on treatment unnecessarily. To assess this issue, we set out to learn how neurologists are making clinical decisions regarding CIDP in the midst of high information flow and multiple guidelines. Thus, we performed an online survey with 100 board-certified community neurologists to better understand the practice patterns of community neurologists from university-and nonuniversity-affiliated practices in the CIDP field.
MATERIALS AND METHODS

Study Design and Methods
This study was designed to collect quantitative cross-sectional survey data from community neurologists. A 10-minute online survey was administered to investigate the patterns of treatment among 100 neurologists who manage patients diagnosed with CIDP. This group included treaters from university-and nonuniversity-affiliated practices. Survey questions were developed by all 4 authors (DG, PN, JDE and JK) and finalized through discussion and input from all. The online survey underwent a pilottest with 2 community neurologists to ensure questions were worded appropriately, response sets were comprehensive, no salient questions had been omitted, etc. Each of the 2 test physicians progressed through the online survey while simultaneously participating in a telephone interview with PN. Information from these 2 pilot tests was not included in the data analysis for the 100 community neurologists.
The 42-item self-administered questionnaire (Appendix 1) was designed to obtain information about the guidelines, clinical features, and electrophysiologic and laboratory evaluations that the respondents typically use for diagnosing CIDP and deciding on initial therapy. If the chosen therapy was IVIg, we explored their choices for typical induction and maintenance IVIg dosages, interval of administration, length of therapy, weaning protocols, and how they identify and treat relapses. In addition, the respondents were asked about the outcome measures they typically use for determining response to therapy and about their approach to patient education, especially regarding disease and expectations for treatment. For brevity, we refer to corticosteroids as "steroids" throughout this manuscript.
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All quantitative survey data were collected in December 2016. The 100 community neurologists were recruited from the e-Rewards Medical panel, which consisted of physicians who opted to be panel members and who were paid for their time and opinions. E-Rewards Medical is a leading provider of an online survey platform to the professional healthcare community. Email invitations for participation in this study were sent from e-Rewards to a sample of 1,200 of its panelists, who remained anonymous to the investigators in this study. To qualify to participate, a respondent had to specialize in neurology; practice in the United States; have been in practice for at least 2 years since residency; and have treated or have consulted on at least 2 CIDP patients per year. Physicians practicing in the state of Vermont were excluded due to legal restrictions against online survey participation. All potential respondents were recruited by email invitation, which provided a general description of the survey topic (ie, "CIDP Patient Management") and a link by which to access the online survey. Each invitation contained a unique identification that prevented any one respondent from taking the survey more than once. No patient data were obtained, and no questions were asked of the participants that would help in identifying them. All participant data were de-identified. Hence, this study was exempt from requiring institutional review board approval under United States Code of Federal Regulations Title 45 Part 46.101(b) (2) . The study did receive a formal Letter of Exemption from the Chesapeake IRB.
Statistical Analysis
Descriptive statistics were performed using T-tests to evaluate differences across ratio variables, including those between board certification subgroups, practice settings of the community neurologists, and years in practice. Statistical significance was assessed at the alpha level of <0.05. Descriptive analyses were performed using SPSS (Version 23.0). Data analysis was done by PN. Grifols and the authors of this manuscript did not have knowledge of physician identity.
RESULTS
Demographics of Community Neurologists
The online survey of the 100 community neurologists took place December 7 to 14, 2016. The respondents represented 31 of the 50 states in the United States (Figure 1) . 
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A C C E P T E D M A N U S C R I P T demographics data of the respondents. The average survey-completion time was 12 minutes. About half (49%) of the respondents were in a university-affiliated practice; the other 51% were not affiliated with a university. Ninety-six percent of the neurologists were board-certified with some declaring additional board certifications in electrodiagnostic medicine (26%) and neuromuscular medicine (22%). Collectively, this was an experienced group of neurologists, having practiced an average of 17 years (SD, 9 years) since residency and/or training. CIDP, chronic inflammatory demyelinating polyneuropathy; SD, standard deviation. Figure 2 shows the proportions of community neurologists who indicated using a particular guideline or no specific guideline for diagnosing CIDP based on their practice setting. Twenty-seven percent (13 of 49) of university-affiliated and 51% (26 of 51) of nonuniversity-affiliated neurologists reported that they do not routinely use a specific guideline when diagnosing CIDP. Even though the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) guideline [4, 5] is accepted globally for both clinical and research purposes due to its balance between high sensitivity ACCEPTED MANUSCRIPT
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(81%-99%) and specificity (61%-97%) for CIDP, [6] [7] [8] [9] only 13% (6 university-and 7 nonuniversityaffiliated) of the 100 community neurologists reported using the EFNS/PNS guideline. In contrast, 21%
(17 university-and 4 nonuniversity-affiliated) reported using the older 1991 American Academy of Neurology (AAN) criteria, [10] which was created for research purposes and can have 100% specificity for CIDP but a sensitivity as low as 3.6%. [9] When the data were analyzed based on the number of board certifications of each respondent, a higher proportion of community neurologists with multiple board certifications (74% of 34) stated they use a specific guideline when diagnosing CIDP than those with a single neurology board certification (55% of 66). Still, only 12% of the 34 neurologists with multiple board certifications reported using the EFNS/PNS guideline. weakness (87%), progression of symptoms over 8 weeks (86%), and total absence of deep tendon reflexes (84%). Unexpectedly, many of the respondents cited features that are not typically associated with CIDP, such as autonomic involvement (31%), pain (29%), and cranial nerve involvement (18%).
Although the majority of physicians (56%-87%) recognized the 4 most useful electrophysiological features as slow nerve conduction velocity, prolonged distal latency, temporal dispersion of CMAP, and prolonged F waves (Figure 4) , approximately half endorsed extraneous features that do not help in making a CIDP diagnosis (eg, absent distal latency motor unit number estimate, and jitter on single fiber EMG). These preferences did not differ significantly based on the respondents' practice setting or board certification (data not shown). As for the ability to recognize various presentations of CIDP, community neurologists identified the following as well-recognized presentations of CIDP ( Figure 5 ): "pure motor CIDP" (75%), "typical CIDP" (69%), "pure sensory CIDP" (65%), and "asymmetric CIDP" (60%). As anticipated, 98% of neurologists were aware that CIDP can present in atypical forms, but many may not appreciate the clear phenotypes that have been described. For example, 47% selected "Miller-Fisher CIDP." Miller-Fisher is a variant of Guillain-Barré Syndrome, not CIDP. In addition, more than one third of the respondents considered "pain" (37%) and "fatigue" (35%) to be indicative of medically significant inflammatory neuropathies requiring treatment (data not shown), yet pain and fatigue are less reliable prognostic indicators and are generally not used to guide dosing decisions. [11, 12] ACCEPTED MANUSCRIPT
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Initial Therapy of Choice
As for therapy preferences, 44% of the community neurologists reported using IVIg alone as their first choice of therapy ( Figure 6 ). Of note, 24% reported using steroids and IVIg together in first-line, even though the EFNS/PNS guideline does not support combination therapy for initial treatment. [5] Steroid alone was the first choice of therapy for 20%, but only a quarter of those respondents reported their preference for steroids was related to lower cost.
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3 IVIg Dosing for Induction and Maintenance
For calculating IVIg dosages, 67% of all community neurologists reported using the patient's actual weight, 25% preferred adjusted or ideal weight, and 8% chose a set dosing regimen in adult patients regardless of weight. When the data were analyzed based on practice setting, a statistically significant higher proportion of nonuniversity-affiliated neurologists (78% of 51) reported using actual weight than those in university-affiliated practices (55% of 49) (P<.05). For the initial IVIg treatment, only 55% of the 100 respondents declared using the recommended loading dose of 2.0 g/kg; whereas, 39% reported using a loading dose of 0.3 kg to 0.6 kg per month, every 2 to 4 weeks, which is a dosing regimen more commonly used in immune globulin replacement. For the subsequent maintenance period, As for how to determine treatment response, the most frequently selected outcome measures
were Medical Research Council manual muscle strength testing (74%), gait assessment (68%), patient self-reported improvement (64%), and grip strength (61%). The Inflammatory Neuropathy Cause and Treatment scale for disability was chosen by about 30% of the 100 community neurologists, and the patient-reported inflammatory Rasch-built overall disability scale was chosen by only 17%. Six percent of the respondents chose "none of these." Even more unanticipated was that 21% had made decisions to increase IVIg dosing via phone conversation with their patients in the absence of any objective data.
4 Weaning Off IVIg
When asked to select the best description(s) of how the respondents counsel patients during initiation of IVIg treatment for CIDP, about 1 out of 3 community neurologists reported not discussing weaning off of IVIg therapy, and approximately 1 out of 10 tell patients that they will be on IVIg for life (data not shown). Twenty-two percent tell their patients "that we will give one dose to see if it works." Although 70% reported telling their patients "that we will treat for X time to see if IVIg works," only 39%
reported telling their patients "that we will attempt to discontinue IVIG at some point in the future ."
When asked about the percentage of CIDP patients the respondents are able to wean off IVIg, the neurologists reported that approximately 38% of their patients (SD, 22%; median, 30%; range 5%-100%) can be weaned from IVIg therapy. Once weaned, about two thirds of patients return to the office
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for follow-ups within 3 months; the remaining one third have no definite follow-up plan and are seen only "as needed," which may contribute to the reluctance of patients to wean off IVIg.
There was no clear consensus among community neurologists on the duration of maintenance prior to weaning (Figure 7) . When we performed a subgroup analysis on the data based on practice setting, university-affiliated neurologists were less likely to commit patients to IVIg for more than 3 months if the patient did not exhibit any sign of improvement on IVIg (data not shown). There is also a need for more education about CIDP diagnosis and treatment, especially on atypical CIDP phenotypes.
We will not discuss details about evidence-based dosing regimens for treatments of CIDP here, as this topic has been thoroughly discussed elsewhere. [14] However, it is worth pointing out that regardless of the choice of CIDP therapy, treating CIDP requires a short-term induction period with the main objective being maximal recovery of functional disabilities and a long-term maintenance period in which the goal is to prevent deterioration, or ideally achieve remission. [5, 15] The 2010 EFNS/PNS guideline [5] recommends IVIg, steroids, or plasma exchange as first-line therapies to be offered to patients with CIDP and states that IVIg has the strongest evidence supporting its use. While the majority of published evidence, [16] [17] [18] [19] [20] support using a total loading dose of 2.0 g/kg IVIg over 2 to 5 consecutive days, almost half of the respondents reported using a maximum IVIg induction dose of less than 2.0 g/kg in patients who failed to respond. This lower dosing regimen leads us to wonder whether those patients
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A C C E P T E D M A N U S C R I P T did not respond because they were truly nonresponsive to IVIg or because they had received suboptimal loading doses of 0.3 kg to 0.6 kg per month, every 2 to 4 weeks, which is a replacement regimen for immunodeficiency, [13] not an autoimmune dosing regimen needed for patients with CIDP.
As for steroid use, the recently published Cochrane Database of Systematic Reviews [2] stated that the evidence supporting steroid use is low yet noted that steroids are commonly used due to their broad availability, low cost, and ease of use. One would assume that the choice to use steroids is costrelated, but less than a quarter of the community neurologists who opt to use steroids in first-line said that they would do it for cost/payer mandate.
The art of weaning off therapy is another important topic for education. There is no guidelinerecommended weaning protocol. Some publications have suggested it may be better to decrease the dosages and maintain constant intervals to avoid large peak/trough IVIg concentrations, while others choose to increase the interval between treatments. [15, 23] It is reasonable to consider setting clear expectations with patients an essential part of practicing medicine. Patients should be aware of how the treatment regimen would be administered, including specific details regarding how attempts will be made to wean therapy and under what conditions weaning is appropriate. We agree with other authors [12] that it is important to explain the need to reduce and withdraw from treatment before treatment is initiated.
Sometimes, patients are hesitant to wean IVIg, but they are more likely to comply with regular trials of weaning if the conversation takes place early and they are informed of warning signs that might indicate they are not tolerating weaning. Unfortunately, expectations of treatment are not always discussed clearly in real-world practice. One third of the community neurologists in this survey reported not discussing weaning with their patients, and about one tenth tell patients that they will be on IVIg for life. 
Limitations
This survey was focused predominantly on CIDP diagnosis and use of IVIg in treatment. It did not assess all of the barriers for why physicians do not follow clinical practice guidelines, such as time constraints, the relative rareness of a CIDP diagnosis, the multiplicity of neurologic diseases with which a community neurologist must be familiar, patient demands for treatment among many others. Because guidelines do not recommend combination therapy as the initial treatment for CIDP, we did not collect detailed information on the use of steroid and IVIg. We also did not collect information regarding weaning off steroids. It would have been interesting to explore these aspects of CIDP management.
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A small number of physicians reported caring for an extremely large number of CIDP patients, which was unexpected but analyses without the responses from these outliers did not substantially change the results. This study reports the opinions of physicians in the United States, and thus the results may not be extrapolated to the behaviors of physicians from other countries. The nature of the e-Rewards panel may have affected how the panel filled out the form, although it is difficult to know if it would create any specific biases. That said, having representation from the majority of 50 states gives a general flavor of how CIDP is being treated throughout the country.
The results reflect the perceptions of the survey respondents. Barriers to adherence in different situations may reflect the variety of experiences of the respondents.
CONCLUSIONS:
CIDP treatment varied among the community neurologists in this study. The majority of neurologists in our quantitative survey were not familiar with the EFNS/PNS guidelines and did not routinely use any particular guideline to diagnose or treat CIDP. The majority of community neurologists were familiar with the clinical presentation of typical CIDP but were not familiar with atypical phenotypes.
They often administered IVIg doses that are lower than the recommended doses for both induction and maintenance; they also dosed less frequently. The community neurologists relied heavily, and sometimes exclusively, on subjective patient reports. In addition, they reported using combination therapy (steroids and IVIg) and often provided nonspecific information on the duration and expectations of IVIg treatment. These findings led us to believe there remains a need for a guideline on CIDP diagnosis and treatment that is brief, clear, and actionable, in particular stressing the need for objective outcomes when determining response to therapy. Furthermore, it may be impactful to pursue proactive changes (eg, more IT innovations that support clinical decisions, enhanced training for medical students, residents, fellows, and practicing physicians on guideline usage, patient education through CIDP Foundation, and greater access to recognized experts) to support guideline adoption and adherence.
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